Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Imatinib Mesylate in Resistant CML
NCT00053248Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2002
- Primary completion
- Jun 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in chronic myelogenous leukemia (CML), sponsored by OHSU Knight Cancer Institute. Started Oct 2002; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00053248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053248.